Diabetes Care, Vol 16, Issue 8 1124-1130, Copyright © 1993 by American Diabetes Association

ARTICLES

Glycemic actions of alanine and terbutaline in IDDM

BV Wiethop and PE Cryer
Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.

OBJECTIVE--To test the hypothesis that the amino acid Ala and the beta 2-adrenergic agonist terbutaline raise plasma glucose concentrations substantially, and do so through different mechanisms, in IDDM patients. RESEARCH DESIGN AND METHODS--We administered these (Ala: 20 and 40 g, orally; terbutaline: 2.5 and 5.0 mg orally and 0.25 mg subcutaneously) and placebos in random sequence to 6 nondiabetic subjects and 6 insulin-infused, initially euglycemic IDDM patients, each studied on six different occasions. Inhaled terbutaline, 0.4 mg, was also tested on a seventh occasion in IDDM patients. RESULTS--Ala administration raised plasma glucagon (P = 0.0219), C-peptide (P = 0.0014), and insulin (P = 0.0094), with no significant change in plasma glucose, in nondiabetic subjects. In patients with IDDM it raised glucagon (P = 0.0001), but not C-peptide or insulin, and plasma glucose rose to 8.3 +/- 0.3 (Ala 20 g, P = 0.0006) and 10.0 +/- 1.0 mM (Ala 40 g, P = 0.0094). Catecholamine levels were unchanged. Terbutaline ingestion raised plasma glucose minimally (e.g., to 6.3 +/- 0.3 mM, P = 0.0133) in nondiabetic subjects but substantially, to 10.2 +/- 1.0 (terbutaline 2.5 mg, P = 0.0078) and 14.0 +/- 0.6 mM (terbutaline 5.0 mg, P = 0.0001), in IDDM patients; subcutaneous terbutaline raised plasma glucose (to a peak of 10.3 +/- 0.7 mM, P = 0.0017) with an initial effect within 10 min, but inhaled terbutaline did so more slowly. In addition to its direct glycemic actions, terbutaline stimulated sympathetic neural norepinephrine release (P = 0.0151) and increased nonesterified fatty acid levels (P = 0.0104), potential indirect glycemic actions. Glucagon levels were unchanged; insulin levels increased in the nondiabetic subjects. CONCLUSIONS--These data demonstrate substantial glycemic responses to Ala and terbutaline, through different mechanisms, in IDDM patients. Thus, Ala and terbutaline represent potential new approaches to the treatment, and perhaps the prevention, of iatrogenic hypoglycemia in IDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. Rossetti, F. Porcellati, N. Busciantella Ricci, P. Candeloro, P. Cioli, K. S. Nair, F. Santeusanio, G. B. Bolli, and C. G. Fanelli Effect of Oral Amino Acids on Counterregulatory Responses and Cognitive Function During Insulin-Induced Hypoglycemia in Nondiabetic and Type 1 Diabetic People Diabetes, July 1, 2008; 57(7): 1905 - 1917. [Abstract] [Full Text] [PDF]

				J. Gromada, I. Franklin, and C. B. Wollheim {alpha}-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains Endocr. Rev., February 1, 2007; 28(1): 84 - 116. [Abstract] [Full Text] [PDF]

				B. Raju, A. M. Arbelaez, S. M. Breckenridge, and P. E. Cryer Nocturnal Hypoglycemia in Type 1 Diabetes: An Assessment of Preventive Bedtime Treatments J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2087 - 2092. [Abstract] [Full Text] [PDF]

				P. E. Cryer Mechanisms of Hypoglycemia-Associated Autonomic Failure and Its Component Syndromes in Diabetes Diabetes, December 1, 2005; 54(12): 3592 - 3601. [Abstract] [Full Text] [PDF]

				B. Raju and P. E. Cryer Loss of the Decrement in Intraislet Insulin Plausibly Explains Loss of the Glucagon Response to Hypoglycemia in Insulin-Deficient Diabetes: Documentation of the Intraislet Insulin Hypothesis in Humans Diabetes, March 1, 2005; 54(3): 757 - 764. [Abstract] [Full Text] [PDF]

				F. Porcellati, S. Pampanelli, P. Rossetti, C. Cordoni, S. Marzotti, L. Scionti, G. B. Bolli, and C. G. Fanelli Counterregulatory Hormone and Symptom Responses to Insulin-Induced Hypoglycemia in the Postprandial State in Humans Diabetes, November 1, 2003; 52(11): 2774 - 2783. [Abstract] [Full Text] [PDF]

				N P Wright and J K H Wales The incidence of hypoglycaemia in children with type 1 diabetes and treated asthma Arch. Dis. Child., February 1, 2003; 88(2): 155 - 156. [Abstract] [Full Text] [PDF]